Business Context and Reporting Period
Company: Calidi Biotherapeutics, Inc. (CLDI)
Filing Type: Form 8-K (Current Report)
Date of Report: August 20, 2025
Event: Entry into a Material Definitive Agreement for a public offering of securities.
Business Stage: Emerging Growth Company focused on pre-clinical studies and clinical trial preparation.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than operational financial performance. Key transaction metrics include:
- Gross Proceeds: Approximately $6.9 million (before underwriting discounts and offering expenses).
- Securities Issued:
- 1,922,764 Common Stock Units (including 450,000 from full exercise of the Over-Allotment Option).
- 1,528,000 Pre-Funded Warrant Units.
- Offering Prices:
- Common Stock Unit: $2.00 per unit.
- Pre-Funded Unit: $1.999 per unit.
- Representative's Warrants: 172,538 warrants issued to the underwriter (Ladenburg Thalmann & Co. Inc.) with an exercise price of $3.00, expiring August 20, 2030.
- Use of Proceeds: Working capital, general corporate purposes, pre-clinical studies, and clinical trial preparation.
Note: The filing does not provide current revenue, profit, cash flow, or debt figures as this is a transaction report, not a periodic financial statement.
Material Changes and Transaction Structure
The primary material change is the significant increase in outstanding equity and potential dilution resulting from the Offering, which closed on August 21, 2025.
- Warrant Terms: Each Common Stock Unit and Pre-Funded Unit includes one Series I Common Warrant exercisable at $2.00 per share, expiring five years from issuance.
- Exercise Limitations: Holders are restricted from exercising warrants if it results in ownership exceeding 4.99% (or up to 19.99% at election) of outstanding shares, unless 61 days' prior notice is given.
- Lock-Up Agreements: Directors and executive officers are subject to a 90-day lock-up period from the closing date.
- Issuance Restrictions: The Company agreed not to issue common stock or equivalents for 60 days post-closing and is restricted from variable rate transactions for six months (with specific exceptions for at-the-market offerings).
Guidance, Outlook, and Risks
Management Commentary: The Company intends to utilize the raised capital to advance its pipeline through pre-clinical studies and clinical trial preparation.
Risks and Contingencies:
- Dilution: The issuance of common stock, pre-funded warrants, and warrants will dilute existing shareholders.
- Market Volatility: As an emerging growth company, the stock price may be subject to significant volatility.
- Execution Risk: Success depends on the ability to effectively deploy capital into clinical trials and achieve regulatory milestones.
Investor Verification Checklist
- Verify the final net proceeds after deducting underwriting discounts and commissions.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific indemnification and termination provisions.
- Confirm the exact number of shares outstanding post-closing to assess dilution impact.
- Monitor the 60-day and 90-day lock-up expiration dates for potential selling pressure.
- Check subsequent filings (Form 10-Q for the quarter ended September 30, 2025) for the final executed agreements and updated financial position.